Multiple myeloma: open trials in China

204 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07239323
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Trial Treatment · Phase 1 · Chongqing Precision Biotech Co., Ltd
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Peking University Third Hospital, Beijing · Sun Yat-sen University Cancer Center, Guangzhou · The 1St Affiliated Hospital of Medical College Zhejiang University, Hangzhou · The 1st Affiliated Hospital Of Medical College Zhejiang University 1, Hangzhou · First Affiliated Hospital SooChow University, Suzhou · Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science, Tianjin · The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an · The First Affiliated Hospital of Xian Jiaotong University, Xi'an
Registry updated 2026-11-03
NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Trial Treatment · Phase 4 · Janssen Research & Development, LLC
Peking University Third Hospital, Beijing · West China Hospital Si Chuan University, Chengdu · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Hospital, Guangzhou · First Hospital, Zhejiang University Medical College, Hangzhou · Jiangsu Province Hospital, Nanjing · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing · Shanghai Fourth People's Hospital, Shanghai · Shanghai Changzheng Hospital, Shanghai · Ruijin Hospital Shanghai Jiao Tong University, Shanghai · The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Peking Union Medical College Hospital, Beijing · Peking University First Hospital, Beijing · Beijing Tongren Hospital CMU, Beijing · The First Hospital of Jilin University, Changchun · The Second Xiangya Hospital of Central South Hospital, Changsha · Changzhou No 2 Peoples Hospital, Changzhou · Beijing Chaoyang Hospital, Chaoyang District · Sichuan Provincial Peoples Hospital, Chengdu · Chongqing University Cancer Hospital, Chongqing · Fujian Meidical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Nanfang Hospital, Guangzhou · No.1 Affiliated Hospital, Medical College of Zhejiang University, Hangzhou · The Second Affiliated Hospital of Zhejiang University, Hangzhou · Harbin Medical University Cancer Hospital, Harbin · Qilu Hospital of Shandong University, Jinan · The First Affliated Hospital Of Nanchang University, Nanchang · Zhongda Hospital Southeast University, Nanjing · Nanjing Drum Tower hospital, Nanjing · The First Affiliated Hospital of Guangxi Medical University, Nanning · Ruijin Hospital Shanghai Jiao Tong University, Shanghai · Shanghai Fourth People's Hospital, Shanghai · Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai · Shengjing Hospital Of China Medical University, Shenyang · Peking University Shenzhen Hospital, Shenzhen · Institute of Hematology and Blood Diseases Hospital, Tianjin · Tianjin Medical University Cancer Institute and Hospital, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Wuhan Tongji Hospital Tongji Medical College, Wuhan · The First Affiliated hospital of Xiamen University, Xiamen · The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Peking University People's Hospital, Beijing · Peking University First Hospital, Beijing · Sichuan Provincial Peoples Hospital, Chengdu · Sun Yat-sen University Cancer Center, Guangzhou · First Affiliated Hospital of Zhejiang University, Hangzhou · Nanjing Drum Tower hospital, Nanjing · The First Affiliated Hospital of Guangxi Medical University, Nanning · Shanghai Fourth People's Hospital, Shanghai · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Wuhan Tongji Hospital Tongji Medical College, Wuhan · The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Registry updated 2026-11-03
NCT07914556
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
Trial Treatment · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd.
Shanghai Jiao Tong University School of Medicine - Ruijin Hospital, Shanghai
Registry updated 2026-11-03
NCT06006741
Universal CAR-T Cells Targeting Multiple Myeloma
Trial Treatment · Phase 1 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-11-02
NCT06429150
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Trial Treatment · Phase 1/2 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-11-02
NCT06435910
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Trial Treatment · Phase 1 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-11-02
NCT07910903
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Keymed Biosciences Co.Ltd
Institute of Hematology & Blood Diseases Hospital, Tianjin
Registry updated 2026-11-02
NCT03271632
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Trial Treatment · Phase 1/2 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-10-30
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Beijing · Beijing · Beijing · Beijing · Changsha · Changsha · Chongqing · Deyang · Guangzhou · Guangzhou · Guangzhou · Hangzhou · Kunming · Linhai · Liuzhou · Luoyang · Nanjing · Nanning · Ningbo · Qingdao · Shanghai · Shanghai · Shenyang · Shenzhen · Shijiazhuang · Taiyuan · Taiyuan · Tianjin · Ürümqi · Wenzhou · Wuhan · Wuxi · Xiamen · Xi'an · Xi'an · Zhengzhou
Registry updated 2026-10-30
NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · AstraZeneca
Beijing · Changsha · Guangzhou · Shenyang
Registry updated 2026-10-30
NCT07907211
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Trial Treatment · Phase 4 · Chen Lijuan
The First Affiliated Hospital with Nanjing Medical University, Nanjing
Registry updated 2026-10-30
NCT07903636
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, 300000, Tianjin
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Peking University Third Hospital, Beijing · The First Hospital of Jilin University, Changchun · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Southern Medical University Nanfang Hospital, Guangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Nanjing Drum Tower hospital, Nanjing · Tongji University - Shanghai Fourth People's Hospital, Shanghai · The First Affiliated Hospital of Soochow University, Suzhou · Institute of hematology&blood disease hospital, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Registry updated 2026-10-27
NCT07106684
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-10-27
NCT07106710
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-10-27
NCT07106736
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-10-27
NCT07322159
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Early phase 1 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-10-27
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking University Third Hospital, Beijing · Beijing Chao-Yang Hospital, Beijing · Peking University Peoples Hospital, Beijing · Hunan Cancer Hospital, Changsha · Chongqing Cancer Hospital, Chongqing · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang · Jiangsu Province Hospital, Nanjing · QingDao Municipal Hospital, Qingdao · Affiliated Zhongshan Hospital of Fudan University, Shanghai · Shanghai Fourth Peoples Hospital Affiliated to Tongji University, Shanghai · The First Hospital of China Medical University, Shenyang · The Second Hospital of Hebei Medical University, Shijiazhuang · Tianjin Medical University General Hospital, Tianjin · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch, Tianjin · Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan · The First Affiliated hospital of Xiamen University, Xiamen · The First Affiliated Hospital of Zhengzhou University, Zhengzhou · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-26
NCT07830485
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-10-26
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Beijing · Shanghai
Registry updated 2026-10-21
NCT07409246
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1 · AbbVie
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 279207, Hangzhou · Institute of Hematology and Blood Diseases Hospital /ID# 279208, Tianjin
Registry updated 2026-10-20
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Tianjin
Registry updated 2026-10-15

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error